Exploring N1-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 197-202

  Ain, Qurrat Ul ^a,e   Greig, Nigel H ^b   Nawaz, Muhammad S ^a   Rashid, Sajid ^c   Kamal, Mohammad A ^b,d  

^a COMSATS Institute of Information Technology ^*  (Pakistan)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c QUAID I AZAM UNIVERSITY   (Pakistan)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

5type 2 diabetes; Docking; Fluorobenzylcymserine; Lipoxygenase

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; N1 P FLUOROBENZYL CYMSERINE; UNCLASSIFIED DRUG; N1-P-FLUOROBENZYLCYMSERINE; NEUROPROTECTIVE AGENT; PHYSOSTIGMINE;

ALZHEIMER DISEASE; ARTICLE; BINDING KINETICS; DEGENERATIVE DISEASE; GENETIC POLYMORPHISM; MOLECULAR DOCKING; MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; ARACHIDONATE 5-LIPOXYGENASE; BINDING SITES; DIABETES MELLITUS, TYPE 2; HUMANS; LIPOXYGENASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; MUTATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PHYSOSTIGMINE; PROTEIN CONFORMATION; PROTEIN STABILITY;

EID: 84904467781     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660136     Document Type: Article

References (37)

1. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-6.
2. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842-7.
3. Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabet Med 2011; 28: 1463-75.
4. Schmidt R, Launer LJ, Nilsson LG, et al. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004; 53: 687-92.
5. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994, 37: 643-50.
6. Kamal A, Biessels GJ, Urban IJ, Gispen WH. Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression. Neuroscience 1999; 90: 737-45.
7. Magarinos AM, McEwen BS. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci USA 2000; 97: 11056-61.
8. Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 2002; 946: 221-31.
9. Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006; 2(3): 159-66.
10. Abbatecola AM, Olivieri F, Corsonello A, et al. Genome-wide association studies: is there a genotype for cognitive decline in older persons with type 2 diabetes? Curr Pharm Des 2011; 17(4): 347-56.
11. Priyadarshini M, Kamal MA, Greig NH, et al. Alzheimer disease and type 2 diabetes: Exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
12. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012; 166: 1586-99.
13. Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007; 82: 1-27.
14. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 2011; 10: 391-403.
15. Tweedie D, Ferguson RA, Fishman K, et al. Tumor necrosis factor- α synthesis inhibitor 3:6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 2012; 9: 106.
16. Ho YS, Poon DC, Chan TF, Chang RC. From small to big molecules: how do we prevent and delay the progression of agerelated neurodegeneration? Curr Pharm Des 2012; 18: 15-26.
17. Mandel SA, Weinreb O, Amit T, Youdim MB. Molecular mechanisms of the neuroprotective/neurorescue action of multitarget green tea polyphenols. Front Biosci 2012; 4: 581-98.
18. Reale M, Pesce M, Priyadarshini M, Kamal MA, Patruno A. Mitochondria as an easy target to oxidative stress events in Parkinson's disease. CNS Neurol Disord Drug Targets 2012; 11: 430-8.
19. Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007; 82: 1-27.
20. Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal antiinflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007, 64: 1403-18.
21. Doherty GH. Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories. Neurosci Bull 2011; 27: 366-82.
22. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011, 3: 90cm17.
23. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5- Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007; 32: 332-41.
24. Rådmark O, Samuelsson B. Regulation of the activity of 5- lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun 2010; 396: 105-10.
25. Mehrabian M, Schulthess FT, Nebohacova M, et al. Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia 2008; 51(6): 987-8.
26. Ben-Asher E, Lancet D. 5-Lipoxygenase activating protein (ALOX5AP): association with cardiovascular infarction and stroke. Isr Med Assoc J 2004; 6(5): 318-9.
27. Yoshida T, Kato K, Yokoi K, et al. Association of genetic variants with chronic kidney disease in Japanese individuals with type 2 diabetes mellitus. Int J Mol Med 2009; 23(4): 529-37.
28. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat Struct Biol 1997, 4: 1003-9.
29. Charlier C, Hénichart JP, Durant F, Wouters J. Structural insights into human 5-lipozygenase inhibition: combined ligand-based and target-based approach. J Med Chem 2006; 49(1): 186-95.
30. Greig NH, Yu QS, Brossi A, Matin E, Lahiri DK, Darvesh S. Butyrylcholinesterase, the Cinderella cholinesterase, as a drug target for Alzheimer's diseases and related dementias. Med Chem Alzheimers Dis 2008; 79-109.
31. Kamal MA, Al-Jafari AA, Yu QS, Greig NH. A Kinetic Analysis of the Inhibition of Cymserine with Human Butyrylcholinesterase. Biochem Biophys Acta 2006; 1760(2): 200-6.
32. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102(47): 17213-8.
33. Gilbert NC, Bartlett SG, Waight MT, et al. The structure of human 5-lipoxygenase. Science 2011; 331(6014): 217-9.
34. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modeling. Bioinformatics 2006; 22(2): 195-201.
35. Castrignanò T, De Meo PD, Cozzetto D, Talamo IG, Tramontano A. The PMDB Protein Model Database. Nucleic Acid Res 2006; D306-9.
36. Kuhn H, Anton M, Gerth C, Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis- resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol 2003; 23(6): 1072-6.
37. Bai C, Matsui E, Ohnishi H, et al. A novel polymorphism, E254K, in the 5-lipoxygenase gene associated with bronchial asthma. Int J Mol Med 2008; 21(2): 139-44.